BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21750091)

  • 21. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
    Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
    Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML.
    Jo A; Mitani S; Shiba N; Hayashi Y; Hara Y; Takahashi H; Tsukimoto I; Tawa A; Horibe K; Tomizawa D; Taga T; Adachi S; Yoshida T; Ichikawa H
    Leukemia; 2015 May; 29(5):1076-83. PubMed ID: 25567132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved classification of MLL-AF9-positive acute myeloid leukemia patients based on BRE and EVI1 expression.
    Noordermeer SM; Monteferrario D; Sanders MA; Bullinger L; Jansen JH; van der Reijden BA
    Blood; 2012 May; 119(18):4335-7. PubMed ID: 22555662
    [No Abstract]   [Full Text] [Related]  

  • 24. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
    Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
    Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia.
    Weisser M; Kern W; Schoch C; Tschulik C; Hiddemann W; Haferlach T; Schnittger S
    Leuk Lymphoma; 2006 Dec; 47(12):2645-7. PubMed ID: 17169810
    [No Abstract]   [Full Text] [Related]  

  • 26. Acute panmyelosis with myelofibrosis with EVI1 amplification.
    Grygalewicz B; Woroniecka R; Pastwińska A; Rygier J; Krawczyk P; Borg K; Makuch-Łasica H; Patkowska E; Pieńkowska-Grela B
    Cancer Genet; 2012 May; 205(5):255-60. PubMed ID: 22682625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
    Gröschel S; Sanders MA; Hoogenboezem R; de Wit E; Bouwman BAM; Erpelinck C; van der Velden VHJ; Havermans M; Avellino R; van Lom K; Rombouts EJ; van Duin M; Döhner K; Beverloo HB; Bradner JE; Döhner H; Löwenberg B; Valk PJM; Bindels EMJ; de Laat W; Delwel R
    Cell; 2014 Apr; 157(2):369-381. PubMed ID: 24703711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.
    Vázquez I; Maicas M; Marcotegui N; Conchillo A; Guruceaga E; Roman-Gomez J; Calasanz MJ; Agirre X; Prosper F; Odero MD
    Proc Natl Acad Sci U S A; 2010 Nov; 107(44):E167-8; author reply E169-70. PubMed ID: 20930122
    [No Abstract]   [Full Text] [Related]  

  • 29. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
    Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
    Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
    Russell M; List A; Greenberg P; Woodward S; Glinsmann B; Parganas E; Ihle J; Taetle R
    Blood; 1994 Aug; 84(4):1243-8. PubMed ID: 8049440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target.
    Yamamoto H; Lu J; Oba S; Kawamata T; Yoshimi A; Kurosaki N; Yokoyama K; Matsushita H; Kurokawa M; Tojo A; Ando K; Morishita K; Katagiri K; Kotani A
    Sci Rep; 2016 Jan; 6():19204. PubMed ID: 26754824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2.
    Gómez-Benito M; Conchillo A; García MA; Vázquez I; Maicas M; Vicente C; Cristobal I; Marcotegui N; García-Ortí L; Bandrés E; Calasanz MJ; Alonso MM; Odero MD
    Br J Cancer; 2010 Oct; 103(8):1292-6. PubMed ID: 20842122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26.
    Morishita K; Parganas E; William CL; Whittaker MH; Drabkin H; Oval J; Taetle R; Valentine MB; Ihle JN
    Proc Natl Acad Sci U S A; 1992 May; 89(9):3937-41. PubMed ID: 1570317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.
    Mochizuki N; Shimizu S; Nagasawa T; Tanaka H; Taniwaki M; Yokota J; Morishita K
    Blood; 2000 Nov; 96(9):3209-14. PubMed ID: 11050005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.
    Lavallée VP; Gendron P; Lemieux S; D'Angelo G; Hébert J; Sauvageau G
    Blood; 2015 Jan; 125(1):140-3. PubMed ID: 25331116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
    Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome.
    Levy ER; Parganas E; Morishita K; Fichelson S; James L; Oscier D; Gisselbrecht S; Ihle JN; Buckle VJ
    Blood; 1994 Mar; 83(5):1348-54. PubMed ID: 8118036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EVI1 drives leukemogenesis through aberrant ERG activation.
    Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
    Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
    J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.